Can pregnant women use Acalabrutinib?

There are currently relatively limited safety data on the use of Acalabrutinib (Acalabrutinib) in pregnant women, so the potential benefits and harms must be carefully weighed when considering using this drug. Acotinib is a BTK inhibitor that is mainly used to treat B-cell lymphoma, especially adult patients with chronic lymphocytic leukemia (CLL).

Drug safety studies in pregnant women are often restricted by ethical and regulatory considerations, so safety data for most drugs are based on animal studies and limited human experience. In the case of acotinib, adequate studies in pregnant women have not been conducted to determine its exact safety during pregnancy.

BTK inhibitors have shown embryotoxic effects in animal studies, so the use of acotinib may be potentially risky for pregnant women, especially in the early stages of pregnancy. In pregnant women or women who may be pregnant, doctors usually carefully evaluate the potential benefits versus risks before deciding whether to continue using acotinib or whether alternative treatments need to be considered.

If a patient requires acotinib treatment before or during pregnancy, it is recommended to consult a medical professional before using this drug. The doctor will evaluate the patient's overall health, severity of disease, and other treatment options, and work with the patient to develop the most appropriate treatment plan to maximize the safety of the mother and fetus.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.